Entrada Therapeutics, Inc. (TRDA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Entrada Therapeutics, Inc. (TRDA) trades at $7.60 with AI Score 15/100 (Grade F). Entrada Therapeutics, Inc. is a biotechnology company focused on developing endosomal escape vehicle (EEV) therapeutics for neuromuscular diseases. Market cap: $295M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026TRDA stock analysis for 2026: Analysts have set a consensus price target of $20.50 for Entrada Therapeutics, Inc., suggesting 169.7% upside from the current price of $7.60. The AI MoonshotScore is 15/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
TRDA: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Entrada Therapeutics, Inc. (TRDA) Healthcare & Pipeline Overview
Entrada Therapeutics, Inc. is a biotechnology firm specializing in endosomal escape vehicle (EEV) therapeutics for neuromuscular diseases. Their proprietary EEV platform aims to deliver oligonucleotide, antibody, and enzyme-based programs, with a focus on addressing unmet needs in Duchenne muscular dystrophy and myotonic dystrophy type 1.
What Is the Investment Thesis for TRDA?
Entrada Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's proprietary EEV platform holds the potential to revolutionize the treatment of neuromuscular diseases by enhancing intracellular drug delivery. The lead product candidate, ENTR-601-44, targeting Duchenne muscular dystrophy and myotonic dystrophy type 1, represents a significant value driver, with potential for substantial market share if clinical trials are successful. However, the company's negative profit margin of -2895.1% and gross margin of -598.0% highlight the significant financial challenges and reliance on future clinical and commercial success. Upcoming clinical trial results for ENTR-601-44 will be a key catalyst. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
TRDA Key Highlights
Market capitalization of $295M reflects investor expectations for Entrada's pipeline and EEV technology.
- Negative profit margin of -2895.1% indicates substantial ongoing investment in research and development.
- Gross margin of -598.0% highlights the current lack of revenue-generating products.
- Beta of -0.15 suggests the stock is less volatile than the overall market.
- No dividend is currently paid, reflecting the company's focus on reinvesting earnings into research and development.
Who Are TRDA's Competitors?
TRDA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
| CRMD CorMedix Inc. | $8.33 | -2.19% | $654M | 95 |
| ZVRA Zevra Therapeutics, Inc. | $11.89 | -1.98% | $703M | 93 |
| GNFTF Genfit S.A. | $16.28 | -1.33% | $816M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TRDA's Key Strengths?
Proprietary EEV technology platform.
- Focus on underserved neuromuscular disease market.
- Lead product candidate in preclinical development.
- Experienced management team.
What Are TRDA's Weaknesses?
Early-stage company with no approved products.
- High reliance on preclinical and clinical trial success.
- Negative profit and gross margins.
- Limited financial resources.
What Could Drive TRDA Stock Higher?
Preclinical data release for ENTR-601-44 in Duchenne muscular dystrophy.
- Initiation of Phase 1 clinical trial for ENTR-601-44 in healthy volunteers.
- Continued development of EEV-PMO-CAG for myotonic dystrophy type 1.
- Expansion of the EEV platform to target new therapeutic areas.
What Are the Key Risks for TRDA?
Financial-distress signal — its Altman Z-Score of 0.15 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-57.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for ENTR-601-44 or other product candidates.
- Regulatory delays or rejection of marketing applications.
- Competition from other companies developing treatments for neuromuscular diseases.
- Dependence on securing additional funding to support research and development.
- Intellectual property challenges or infringement claims.
What Are the Growth Opportunities for TRDA?
- Expansion into New Therapeutic Areas: Entrada has the opportunity to leverage its EEV platform to develop treatments for other diseases beyond neuromuscular disorders. The platform's ability to enhance intracellular drug delivery could be applied to a wide range of therapeutic areas, including oncology, immunology, and rare genetic diseases. This expansion could significantly increase Entrada's market potential and diversify its revenue streams. The timeline for this expansion depends on the success of ongoing research and development efforts and could begin within the next 3-5 years.
- Strategic Partnerships and Collaborations: Entrada can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its EEV-based therapies. These partnerships could provide Entrada with access to additional funding, expertise, and resources, as well as expand its global reach. Collaborations could focus on specific therapeutic areas or on the development of new EEV-based technologies. Such partnerships could materialize within the next 1-2 years as clinical trials progress.
- Advancement of ENTR-601-44 through Clinical Trials: The successful advancement of ENTR-601-44 through clinical trials represents a significant growth opportunity for Entrada. Positive clinical trial results would validate the EEV platform and demonstrate the efficacy of ENTR-601-44 in treating Duchenne muscular dystrophy and myotonic dystrophy type 1. This would increase the company's valuation and attract further investment. Clinical trial milestones are expected over the next 2-3 years.
- Development of EEV-PMO-CAG for Myotonic Dystrophy Type 1: The development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1 presents another key growth opportunity. This program leverages the EEV platform to deliver a PMO (phosphorodiamidate morpholino oligomer) to correct the underlying genetic defect in DM1. Successful development of EEV-PMO-CAG could provide a significant treatment option for patients with this debilitating disease. Preclinical and early clinical data are anticipated within the next 2 years.
- Geographic Expansion: Entrada can expand its geographic reach by commercializing its therapies in new markets. Initially focusing on the United States and Europe, Entrada could eventually expand into other regions, such as Asia and Latin America. This geographic expansion would increase the company's potential customer base and drive revenue growth. Expansion plans are likely to be implemented following successful clinical trial outcomes and regulatory approvals, potentially within 3-5 years.
What Threats Does TRDA Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Difficulty raising capital.
What Are TRDA's Competitive Advantages?
- Proprietary Endosomal Escape Vehicle (EEV) Technology: Entrada's EEV platform provides a unique and potentially superior method for delivering therapeutics into cells, creating a competitive advantage.
- Patent Protection: Entrada has patents covering its EEV technology and therapeutic candidates, providing a barrier to entry for competitors.
- Focus on Neuromuscular Diseases: Specialization in neuromuscular diseases allows Entrada to develop deep expertise and build relationships with key stakeholders.
- First-Mover Advantage: As an early mover in the EEV field, Entrada has the opportunity to establish itself as a leader and attract top talent.
What Does TRDA Do?
Entrada Therapeutics, Inc., founded in 2016 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative treatments for neuromuscular diseases. Originally incorporated as CycloPorters, Inc., the company rebranded as Entrada Therapeutics in October 2017 to reflect its evolved focus on endosomal escape vehicle (EEV) technology. This proprietary platform is designed to enhance the intracellular delivery of therapeutics, overcoming a significant hurdle in treating diseases that require drugs to reach specific compartments within cells. Entrada's EEV platform supports a diverse portfolio of oligonucleotide, antibody, and enzyme-based programs, targeting a range of neuromuscular conditions. The company's lead product candidate, ENTR-601-44, is currently in preclinical development for the treatment of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). Additionally, Entrada is developing EEV-PMO-CAG for the treatment of DM1, further demonstrating its commitment to addressing this challenging disease. By focusing on improving drug delivery, Entrada aims to develop more effective therapies for patients with limited treatment options.
What Products and Services Does TRDA Offer?
- Develops endosomal escape vehicle (EEV) therapeutics.
- Focuses on treating neuromuscular diseases.
- Utilizes a proprietary EEV platform to enhance intracellular drug delivery.
- Develops oligonucleotide-based therapies.
- Develops antibody-based therapies.
- Develops enzyme-based therapies.
- Conducts preclinical trials for lead product candidates like ENTR-601-44.
- Targets Duchenne muscular dystrophy and myotonic dystrophy type 1.
How Does TRDA Make Money?
- Develops and patents novel EEV-based therapeutics.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA and EMA.
- May partner with larger pharmaceutical companies for commercialization.
- Generates revenue through licensing agreements and product sales.
What Industry Does TRDA Operate In?
Entrada Therapeutics operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for neuromuscular disease treatments is growing, driven by an aging population and advancements in genetic therapies. Entrada's EEV platform aims to differentiate it from competitors by improving drug delivery and efficacy. The company faces competition from established pharmaceutical companies and other biotechnology firms developing treatments for similar indications. Success in this industry requires strong scientific expertise, effective clinical trial execution, and successful commercialization strategies.
Who Are TRDA's Key Customers?
- Patients suffering from neuromuscular diseases like Duchenne muscular dystrophy and myotonic dystrophy type 1.
- Healthcare providers who prescribe and administer Entrada's therapies.
- Hospitals and clinics that utilize Entrada's products.
- Pharmaceutical companies that may partner with Entrada for development and commercialization.
- Research institutions involved in clinical trials and studies.
Forward Outlook
Wall Street analysts project Entrada Therapeutics, Inc. revenue of about $13.2M for fiscal 2026, with EPS near $-3.92. The estimate reflects 6 contributing analysts.
TRDA Valuation & Market Position
With a $295M market cap, Entrada Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, TRDA's quantitative score of 15/100 is below the peer average of 78/100.
Key Financial Metrics
Return on equity for Entrada Therapeutics, Inc. stands at -57.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -55.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -44.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.89 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -50.5%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Entrada Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.15 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Entrada Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Dipal Doshi. TRDA has traded publicly since 2021.
TRDA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Entrada's future prospects, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively, with many traders expressing optimism about the company's innovative therapies and upcoming clinical trials.
- Entrada's strategic partnerships have strengthened its position in the biotech space, leading to increased interest from investors.
- The overall market perception is buoyed by a growing focus on rare disease treatments, aligning with Entrada's mission and enhancing its attractiveness.
Bear Case
- Despite recent positive sentiment, some traders remain cautious about the biotech sector's volatility, which could impact Entrada's stock performance.
- Concerns about regulatory hurdles and the lengthy approval process for new therapies may dampen investor enthusiasm in the short term.
- Market chatter includes skepticism regarding the company's ability to deliver on its ambitious pipeline, leading to mixed community views.
- Recent news coverage has highlighted potential competition in the rare disease space, raising questions about Entrada's market share and future growth.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TRDA Latest News
No recent news available for TRDA.
TRDA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TRDA.
Price Targets
Consensus target: $20.50
TRDA MoonshotScore
What does this score mean?
The MoonshotScore rates TRDA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Dipal Doshi
CEO
Dipal Doshi serves as the Chief Executive Officer of Entrada Therapeutics, leading the company's strategic direction and operations. His background includes extensive experience in the biotechnology and pharmaceutical industries, with a focus on drug development and commercialization. He has held leadership positions at various companies, contributing to the advancement of novel therapies. Doshi's expertise spans across multiple therapeutic areas, including neuromuscular diseases, and he is committed to bringing innovative treatments to patients in need. His educational background includes advanced degrees in science and business.
Track Record: Under Dipal Doshi's leadership, Entrada Therapeutics has focused on advancing its EEV platform and pipeline of therapeutic candidates. Key milestones include the progression of ENTR-601-44 into preclinical development and the expansion of the company's research and development efforts. Doshi has also overseen strategic partnerships and collaborations aimed at accelerating the development and commercialization of Entrada's therapies.
What Investors Ask About Entrada Therapeutics, Inc. (TRDA) — Healthcare
What does the AI Score mean for TRDA?
TRDA holds an AI Score of 15/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Entrada Therapeutics, Inc. is a biotechnology company focused on developing endosomal escape vehicle (EEV) therapeutics for neuromuscular diseases. Their lead product candidate, ENTR-601-44, is …
What does Entrada Therapeutics, Inc. do?
Entrada Therapeutics, Inc. is a biotechnology company specializing in the development of endosomal escape vehicle (EEV) therapeutics, primarily focused on treating neuromuscular diseases. Their proprietary EEV platform aims to enhance the intracellular delivery of drugs, addressing a critical challenge in treating diseases that require therapies to reach specific compartments within cells.
What do analysts say about TRDA stock?
Analyst coverage of Entrada Therapeutics, Inc. (TRDA) is still emerging, reflecting its early-stage development as a biotechnology company. Current sentiment acknowledges the potential of its EEV platform but also highlights the inherent risks associated with preclinical-stage drug development. Key valuation metrics are heavily influenced by expectations for ENTR-601-44 and the broader EEV platform.
What are the main risks for TRDA?
Entrada Therapeutics, Inc. faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as the success of ENTR-601-44 and other product candidates is crucial for the company's valuation. Regulatory hurdles and potential delays in obtaining marketing approvals pose another challenge.
What are the key factors to evaluate for TRDA?
Entrada Therapeutics, Inc. (TRDA) holds an AI score of 15/100 (low). Analysts target $20.50 (+170%). Entrada Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does TRDA data refresh on this page?
TRDA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TRDA's recent stock price performance?
Entrada Therapeutics, Inc. (TRDA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary EEV technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TRDA overvalued or undervalued right now?
Entrada Therapeutics, Inc. (TRDA) is loss-making, so its trailing P/E is negative (-2.9x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Analysts target $20.50 (+170%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TRDA before investing?
Before investing in Entrada Therapeutics, Inc. (TRDA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.